Literature DB >> 12209278

Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.

S Elatrous1, S Nouira, L Ouanes Besbes, S Marghli, M Boussarssar, M Sakkouhi, F Abroug.   

Abstract

OBJECTIVES: To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy. DESIGN. Randomized prospective study.
SETTING: The obstetric ward of the teaching hospital of Monastir Tunisia. PATIENTS: Sixty consecutive pregnant women admitted beyond the 24th week of pregnancy with severe hypertension. INTERVENTION: Patients were randomly assigned to receive intravenously for 1 h either labetalol ( n=30) or nicardipine ( n=30). Treatment was titrated to achieve a 20% lowering of blood pressure (BP). MEASUREMENTS: Maternal BP and heart rate were measured at inclusion and repeatedly during the first hour following the drugs administration. Fetal heart rate was recorded throughout the study period. The main outcome endpoints were the success rate and the length of time needed to achieve the therapeutic goal. The rate of maternal and fetal adverse events and dose adjustments were also analyzed.
RESULTS: Labetalol and nicardipine achieved the 20% lowering in BP in the same proportion (63% and 70% success rates, respectively). Overall nicardipine caused a significantly greater decrease in systolic and diastolic BP. No patient had any episode of hypotension. The length of time to achieve the BP goal was also similar (12 vs. 11 min, respectively). Both drugs were well tolerated except for a moderate tachycardia observed with the use of nicardipine.
CONCLUSION: Nicardipine and labetalol are effective and safe in the initial treatment of severe hypertension of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209278     DOI: 10.1007/s00134-002-1406-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  8 in total

1.  Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage.

Authors:  Santiago Ortega-Gutierrez; Jiz Thomas; Andres Reccius; Sachin Agarwal; Hector Lantigua; Min Li; Amanda M Carpenter; Stephan A Mayer; J Michael Schmidt; Kiwon Lee; Jan Claassen; Neeraj Badjatia; Christine Lesch
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

Review 2.  Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.

Authors:  Kannan Sridharan; Reginald P Sequeira
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

Review 3.  Vascular and cellular calcium in normal and hypertensive pregnancy.

Authors:  Zuzana Adamova; Sifa Ozkan; Raouf A Khalil
Journal:  Curr Clin Pharmacol       Date:  2009-09-01

Review 4.  Pre-eclampsia: an update.

Authors:  Peter von Dadelszen; Laura A Magee
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 5.  Drugs for treatment of very high blood pressure during pregnancy.

Authors:  Lelia Duley; Shireen Meher; Leanne Jones
Journal:  Cochrane Database Syst Rev       Date:  2013-07-31

Review 6.  Antihypertensive Medications for Severe Hypertension in Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Adila Awaludin; Cherry Rahayu; Nur Aizati Athirah Daud; Neily Zakiyah
Journal:  Healthcare (Basel)       Date:  2022-02-09

7.  What is the best drug to prescribe for a young woman in her childbearing years with essential hypertension?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

8.  Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life.

Authors:  Carolien N H Abheiden; Rebecca van Doornik; Annet M Aukes; Wiesje M van der Flier; Philip Scheltens; Christianne J M de Groot
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.